Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2014 16:21 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Public Offering of Common Stock

SAN RAFAEL, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 1,500,000 shares of its common...
March 04, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at the Barclays Global Healthcare Conference in Miami

SAN RAFAEL, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today...
February 26, 2014 16:05 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results

Total Revenue Grows 9.5% in 2013 U.S. Commercial Launch of VIMIZIM™ Underway; Positive CHMP Opinion Received February 20 Financial Highlights ($ in millions, except per share data,...
February 25, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at the Cowen Healthcare Conference in Boston

SAN RAFAEL, Calif., Feb. 25, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today...
February 20, 2014 11:21 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome

SAN RAFAEL, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European...
February 19, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at Two Upcoming Investor Conferences in New York

- 2014 Citi Global Healthcare Conference - 2014 RBC Capital Markets' Global Healthcare Conference SAN RAFAEL, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc....
February 17, 2014 15:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Discuss FDA Approval of VIMIZIM(TM) and Provide Preliminary 2013 Results

- Company to Host Conference Call and Webcast, Tuesday, February 18 at 8:00 a.m. ET - Review of Preliminary 2013 Results and 2014 Financial Guidance SAN RAFAEL, Calif., Feb. 17, 2014 (GLOBE...
February 14, 2014 16:30 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome

SAN RAFAEL, Calif., Feb. 14, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved VIMIZIM™...
February 13, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Presents 15 Abstracts From Basic Research to Clinical Trials at Lysosomal Disease Network's 10th Annual WORLDSymposium(TM)

12 Abstracts on MPS diseases and 3 on Pompe Disease 10-Year Naglazyme® (galsulfase) Data Suggests Increased Survival of MPS VI Patients SAN RAFAEL, Calif., Feb. 13, 2014 (GLOBE NEWSWIRE)...
February 11, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB)

Potential to Add Fourth MPS Treatment to BioMarin Franchise Two presentations at Lysosomal Disease Network's 10th Annual WORLDSymposium™ SAN RAFAEL, Calif., Feb. 11, 2014 (GLOBE NEWSWIRE)...